Induction therapy, routinely implemented in organ transplant procedures, consists of biologic agents to block early immune activation.
1,2 For kidney transplants, lymphodepletion with antithymocyte globulin (ATG) or alemtuzumab has contributed to reducing acute rejection episodes and improving early graft function but remains associated with toxic effects, cytomegalovirus reactivation, and posttransplant lymphoproliferative disease.
3-5 Targeting interleukin 2-(IL-2) receptor α chain on activated T lymphocytes can reduce acute rejection episodes in kidney transplant when combined with standard immunosuppression.
2